210 related articles for article (PubMed ID: 28595194)
1. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
4. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
Sandborn WJ; Melmed GY; McGovern DP; Loftus EV; Choi JM; Cho JH; Abraham B; Gutierrez A; Lichtenstein G; Lee SD; Randall CW; Schwartz DA; Regueiro M; Siegel CA; Spearman M; Kosutic G; Pierre-Louis B; Coarse J; Schreiber S
Aliment Pharmacol Ther; 2015 Aug; 42(3):330-42. PubMed ID: 26031921
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
Moon W; Pestana L; Becker B; Loftus EV; Hanson KA; Bruining DH; Tremaine WJ; Kane SV
Aliment Pharmacol Ther; 2015 Aug; 42(4):428-40. PubMed ID: 26081839
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
7. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Loftus EV; Colombel JF; Schreiber S; Randall CW; Regueiro M; Ali T; Arendt C; Coarse J; Spearman M; Kosutic G
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1753-1762. PubMed ID: 27464588
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab pegol for induction of remission in Crohn's disease.
Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018
[TBL] [Abstract][Full Text] [Related]
9. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
11. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.
Melmed GY; McGovern D; Schreiber S; Kosutic G; Spearman M; Coarse J; Sandborn WJ
Curr Med Res Opin; 2016 Dec; 32(12):1937-1941. PubMed ID: 27494777
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Allez M; Vermeire S; Mozziconacci N; Michetti P; Laharie D; Louis E; Bigard MA; Hébuterne X; Treton X; Kohn A; Marteau P; Cortot A; Nichita C; van Assche G; Rutgeerts P; Lémann M; Colombel JF
Aliment Pharmacol Ther; 2010 Jan; 31(1):92-101. PubMed ID: 19709098
[TBL] [Abstract][Full Text] [Related]
13. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
Vande Casteele N; Feagan BG; Vermeire S; Yassine M; Coarse J; Kosutic G; Sandborn WJ
Aliment Pharmacol Ther; 2018 Jan; 47(2):229-237. PubMed ID: 29159893
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
16. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.
Sandborn WJ; Wolf DC; Kosutic G; Parker G; Schreiber S; Lee SD; Abraham B; Afzali A; Arsenescu RI; Gutierrez A; Spearman M; Coarse J; Feagan BG
Inflamm Bowel Dis; 2017 Jul; 23(7):1047-1056. PubMed ID: 28410341
[TBL] [Abstract][Full Text] [Related]
17. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
[TBL] [Abstract][Full Text] [Related]
18. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
19. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
